This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Aspirin and prevention of cognitive decline in postmenopausal women

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • the use of low dose aspirin as a measure to prevent cognitive decline in postmenopausal women has been investigated in the Women's Health Study
    • cohort study within both arms of the women's health study, a randomised, double blind, placebo controlled trial
    • 6377 women aged 65 or more were given low dose aspirin (100 mg on alternate days) or placebo for a mean of 9.6 years
    • the study authors concluded that the evidence did not support the use of low dose aspirin in postmenopausal women to prevent cognitive decline

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.